infectious diseases

News

GSK antibiotic gepotidacin clears phase 3 gonorrhoea trial

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.

News

FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker th

News

BARDA backs Locus phage therapy for resistant E coli

The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in de

News

FDA clears French syphilis drug imports to tackle shortage

Facing a sharp rise in the number of syphilis cases, the FDA has authorised the importation from France of a life-saving drug for the sexually transmitted infection (STI)

R&D

Novavax: Creating tomorrow’s vaccines today

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines.

News

Novo Nordisk Foundation puts $25m into AMR programme

The Novo Nordisk Foundation has come up with more funding to help battle the scourge of antimicrobial resistance (AMR), putting $25 million into a non-profit accelerator p

GSK antibiotic gepotidacin clears phase 3 gonorrhoea trial

FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen

BARDA backs Locus phage therapy for resistant E coli

FDA clears French syphilis drug imports to tackle shortage

Novavax: Creating tomorrow’s vaccines today

Novo Nordisk Foundation puts $25m into AMR programme

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

infectious diseases

Editor's Picks